

NOVO NORDISK A S
Form 6-K
April 01, 2015
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

April 1, 2015

NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 1 April 2015 – On 30 January 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2015.

Edgar Filing: NOVO NORDISK A S - Form 6-K

Under the programme initiated 30 January 2015, Novo Nordisk will repurchase B shares for an amount up to DKK 3.7 billion in the period from 30 January 2015 to 28 April 2015.

Since the announcement as of 23 March 2015, the following transactions have been made under the programme:

| | Number of B shares | Average purchase price | Transaction value, DKK |
|---------------------------------|-----------------------|---------------------------|---------------------------|
| Accumulated, last announcement | 7,219,481 | | 2,214,224,053 |
| 23 March 2015 | 185,000 | 338.44 | 62,612,103 |
| 24 March 2015 | 170,000 | 343.87 | 58,458,291 |
| 25 March 2015 | 190,000 | 341.88 | 64,957,656 |
| 26 March 2015 | 210,000 | 334.94 | 70,336,371 |
| 27 March 2015 | 165,000 | 370.82 | 61,184,475 |
| 30 March 2015 | 150,000 | 372.99 | 55,949,070 |
| 31 March 2015 | 180,000 | 373.27 | 67,189,230 |
| | | | |
| Accumulated under the programme | 8,469,481 | | 2,214,224,053 |

With the transactions stated above, Novo Nordisk owns a total of 67,108,333 B shares of DKK 0.20, corresponding to 2.5% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2015. As of 31 March 2015, Novo Nordisk has repurchased a total of 8,469,481 B shares equal to a transaction value of DKK 2,654,911,249.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 41,500 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

Further information

Media:

Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com

Investors:

Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com

Daniel Bohsen +45 3079 6376 dabo@novonordisk.com

Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com

Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com

Novo Nordisk A/S
Investor Relations

Novo Allé
2880 Bagsværd
Denmark

Telephone:
+45 4444 8888

Internet:
www.novonordisk.com
CVR no:
24 25 67 90

Company announcement No 24 / 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: April 1, 2015

NOVO NORDISK A/S

Lars Rebien Sørensen,
Chief Executive Officer